Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers
Open accessAbstract
BACKGROUND: Risk-reducing salpingo-oophorectomy (RRSO) is widely used by carriers of BRCA1 or BRCA2 (BRCA1/2) mutations to reduce their risks of breast and ovarian cancer. To guide women and their clinicians in optimizing cancer prevention strategies, we summarized the magnitude of the risk reductions in women with BRCA1/2 mutations who have undergone RRSO compared with those who have not. METHODS: All reports of RRSO and breast and/or ovarian or fallopian tube cancer in BRCA1/2 mutation carriers published between 1999 and 2007 were obtained from a PubMed search. Hazard ratio (HR) estimates were identified directly from the original articles. Pooled results were computed from nonoverlapping studies by fixed-effects meta-analysis. RESULTS: Ten studies investigated breast or gynecologic cancer outcomes in BRCA1/2 mutation carriers who had undergone RRSO. Breast cancer outcomes were investigated in three nonoverlapping studies of BRCA1/2 mutation carriers, four of BRCA1 mutation carriers, and three of BRCA2 mutation carriers. Gynecologic cancer outcomes were investigated in three nonoverlapping studies of BRCA1/2 mutation carriers and one of BRCA1 mutation carriers. RRSO was associated with a statistically significant reduction in risk of breast cancer in BRCA1/2 mutation carriers (HR = 0.49; 95% confidence interval [CI] = 0.37 to 0.65). Similar risk reductions were observed in BRCA1 mutation carriers (HR = 0.47; 95% CI = 0.35 to 0.64) and in BRCA2 mutation carriers (HR = 0.47; 95% CI = 0.26 to 0.84). RRSO was also associated with a statistically significant reduction in the risk of BRCA1/2-associated ovarian or fallopian tube cancer (HR = 0.21; 95% CI = 0.12 to 0.39). Data were insufficient to obtain separate estimates for ovarian or fallopian tube cancer risk reduction with RRSO in BRCA1 or BRCA2 mutation carriers. CONCLUSION: The summary estimates presented here indicate that RRSO is strongly associated with reductions in the risk of breast, ovarian, and fallopian tube cancers and should provide guidance to women in planning cancer risk reduction strategies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The analyses corrected for prophylactic measures, although the effect on contralateral breast cancer prevention was not an endpoint in the article.
“In the analyses we corrected for prophylactic measures, although the effect on CBC prevention 49,50 was not an end point in this article.”
From Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers (2016) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955 · see citing works
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680 · see citing works
Ford, D., Easton, D., Stratton, M. R., Narod, S., Goldgar, D., Devilee, P., Bishop, D., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · American Journal of Human Genetics · doi:10.1086/301749 · Cited by 2,766 · see citing works
Self-citationThe risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Struewing, J., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,399 · see citing works
Breast and Ovarian Cancer Risks Due to Inherited Mutations in <i>BRCA1</i> and <i>BRCA2</i>
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229 · see citing works
Smithers, D. W. (1956) · The Lancet · doi:10.1016/s0140-6736(56)91184-9 · Cited by 1,796 · see citing works
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · JAMA · doi:10.1001/jama.297.13.1465 · Cited by 1,741 · see citing works
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., Veer, L. V., Garber, J. E., Evans, D. G., Isaacs, C. J., Daly, M. B., Matloff, E. T., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012158 · Cited by 1,462 · see citing works
Self-citationRisk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation
Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M. L., Hudis, C. A., Ellis, N. A., Boyd, J. A., Borgen, P. I., Barakat, R. R., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020119 · Cited by 1,250 · see citing works
Self-citationRebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ’t Veer, L., Garber, J. E., Evans, G. R., Narod, S. A., Isaacs, C., Matloff, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.188 · Cited by 1,171 · see citing works
Self-citationWarner, E. (2004) · JAMA · doi:10.1001/jama.292.11.1317 · Cited by 1,168 · see citing works
Leach, M. O., Boggis, C. R. M., Dixon, A. K., Easton, D. F., Eeles, R. A., Evans, D. G., Gilbert, F. J., Griebsch, I., Hoff, R., Kessar, P., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66481-1 · Cited by 1,005 · see citing works
Lakhani, S., van de Vijver, M., Jacquemier, J., Anderson, T., Osin, P., McGuffog, L., & Easton, D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.023 · Cited by 888 · see citing works
Estrogen Therapy and Coronary-Artery Calcification
Manson, J. E., Allison, M. A., Rossouw, J. E., Carr, J. J., Langer, R. D., Hsia, J., Kuller, L. H., Cochrane, B. B., Hunt, J. R., Ludlam, S. E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071513 · Cited by 711 · see citing works
Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Rebbeck, T. R., Levin, A. M., Eisen, A. F., Snyder, C., Watson, P. A., Cannon‐Albright, L., Isaacs, C. J., Olopade, O., Garber, J. E., Godwin, A. K., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1475 · Cited by 670 · see citing works
Self-citationOral Contraceptives and the Risk of Hereditary Ovarian Cancer
Narod, S. A., Risch, H. A., Moslehi, R., Dørum, A., Neuhausen, S. L., Olsson, H. L., Provencher, D. M., Radice, P., Evans, D. G., Bishop, S. E., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390702 · Cited by 612 · see citing works
Anglian Breast Cancer Study Group (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1407 · Cited by 602 · see citing works
Finch, A. (2006) · JAMA · doi:10.1001/jama.296.2.185 · Cited by 601 · see citing works
Kauff, N. D., Domchek, S. M., Friebel, T. M., Robson, M. E., Lee, J., Garber, J. E., Isaacs, C. J., Evans, D. G., Lynch, H. T., Eeles, R. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9626 · Cited by 586 · see citing works
Self-citationNarod, S., Brunet, J., Ghadirian, P., Robson, M., Heimdal, K., Neuhausen, S., Stoppa-Lyonnet, D., Lerman, C., Pasini, B., Ríos, P. D. L., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03258-x · Cited by 557 · see citing works
Survival patterns after oophorectomy in premenopausal women: a population-based cohort study
Rocca, W. A., Grossardt, B. R., de Andrade, M., Malkasian, G. D., & Melton, L. J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70869-5 · Cited by 548 · see citing works
Eisen, A. F., Lubiński, J., Klijn, J. G. M., Møller, P., Lynch, H. T., Offit, K., Weber, B., Rebbeck, T., Neuhausen, S. L., Ghadirian, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7138 · Cited by 442 · see citing works
Self-citationRebbeck, T. R., Friebel, T. M., Wagner, T. M., Lynch, H. T., Garber, J. E., Daly, M. B., Isaacs, C. J., Olopade, O. I., Neuhausen, S. L., Veer, L. V. ‘., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.8151 · Cited by 412 · see citing works
Self-citationOral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Narod, S., Dubé, M.-P., Klijn, J., Lubiński, J., Lynch, H., Ghadirian, P., Provencher, D., Heimdal, K., Møller, P., Robson, M., et al. (2002) · Journal of the National Cancer Institute · doi:10.1093/jnci/94.23.1773 · Cited by 375 · see citing works
Domchek, S. M., Friebel, T. M., Neuhausen, S. L., Wagner, T. M., Evans, D. G., Isaacs, C. J., Garber, J. E., Daly, M. B., Eeles, R. A., Matloff, E. T., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70585-x · Cited by 327 · see citing works
Self-citationTamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update
Gronwald, J., Tung, N., Foulkes, W. D., Offit, K., Gershoni, R., Daly, M. B., Kim‐Sing, C., Olsson, H. L., Ainsworth, P., Eisen, A. F., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21536 · Cited by 253 · see citing works
Modifiers of risk of hereditary breast and ovarian cancer
Narod, S. A. (2002) · Nature reviews. Cancer · doi:10.1038/nrc726 · Cited by 179 · see citing works
Hermsen, B. B. J., Olivier, R. I., Verheijen, R. H. M., van Beurden, M., de Hullu, J. A., Massuger, L. F. A. G., Burger, C. W., Brekelmans, C. T. M., Mourits, M. J. E., de Bock, G. H., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603725 · Cited by 153 · see citing works
Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations
Whittemore, A. S., Balise, R. R., Pharoah, P. D. P., DiCioccio, R. A., Oakley-Girvan, I. A., Ramus, S. J., Daly, M. B., Usinowicz, M. B., Garlinghouse-Jones, K., Ponder, B. A. J., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602239 · Cited by 152 · see citing works
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan, J. M., Boyd, J. A., Kauff, N. D., Robson, M. E., Scheuer, L., Narod, S. A., & Offit, K. (2002) · PubMed · Cited by 152 · see citing works
Self-citationBrohet, R. M., Goldgar, D. E., Easton, D. F., Antoniou, A. C., Andrieu, N., Chang-Claude, J. C., Peock, S., Eeles, R. A., Cook, M., Chu, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.1179 · Cited by 151 · see citing works
Grann, V. R., Jacobson, J. S., Thomason, D., Hershman, D. L., Heitjan, D. F., & Neugut, A. I. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.101 · Cited by 149 · see citing works
Kramer, J. L., Velazquez, I. A., Chen, B. E., Rosenberg, P. S., Struewing, J. P., & Greene, M. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.9199 · Cited by 135 · see citing works
Risk-Reducing Salpingo-Oophorectomy in Patients With Germline Mutations in BRCA1 or BRCA2
Kauff, N. D., & Barakat, R. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3449 · Cited by 133 · see citing works
Self-citationRutter, J. L., Wacholder, S., Chetrit, A., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.14.1072 · Cited by 100 · see citing works
Chang-Claude, J. C., Andrieu, N., Rookus, M. A., Brohet, R. M., Antoniou, A. C., Peock, S., Davidson, R., Izatt, L., Cole, T. R. P., Noguès, C., et al. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0829 · Cited by 88 · see citing works
Potential for Bias in Studies on Efficacy of Prophylactic Surgery for BRCA1 and BRCA2 Mutation
Klaren, H. M., Veer, L. J. V., van Leeuwen, F. E., & Rookus, M. A. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.941 · Cited by 78 · see citing works
Available, N. A. N. (2004) · The Women s Oncology Review · doi:10.1080/14733400400013030 · Cited by 76 · see citing works
Antoniou, A. C., Pharoah, P. D. P., Easton, D. F., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7934 · Cited by 31 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Key steps for effective breast cancer prevention
Britt, K. L., Cuzick, J., & Phillips, K.-A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0266-x · Cited by 992 · see citing works
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Metcalfe, K., Gershman, S., Lynch, H. T., Ghadirian, P., Tung, N., Kim-Sing, C., Olopade, O. I., Domchek, S., McLennan, J., Eisen, A., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.120 · Cited by 232 · see citing works
Self-citationEffects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms
Yue, W., Wang, J., Li, Y., Fan, P., Liu, G., Zhang, N., Conaway, M., Wang, H., Korach, K. S., Bocchinfuso, W., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25207 · Cited by 196 · see citing works
HRT for women with premature ovarian insufficiency: a comprehensive review
Webber, L., Anderson, R. A., Davies, M., Janse, F., & Vermeulen, N. (2017) · Human Reproduction Open · doi:10.1093/hropen/hox007 · Cited by 141 · see citing works
Petrelli, N. J., Winer, E. P., Brahmer, J., Dubey, S., Smith, S., Thomas, C., Vahdat, L. T., Obel, J., Vogelzang, N., Markman, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6171 · Cited by 121 · see citing works
van den Broek, A. J., van ’t Veer, L. J., Hooning, M. J., Cornelissen, S., Broeks, A., Rutgers, E. J., Smit, V. T. H. B. M., Cornelisse, C. J., van Beek, M., Janssen-Heijnen, M. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3942 · Cited by 104 · see citing works
Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe
Marmolejo, D. H., Wong, M. Y. Z., Bajalica-Lagercrantz, S., Tischkowitz, M., Balmaña, J., Patócs, A. B., Chappuis, P., Colas, C., Genuardi, M., Haanpää, M., et al. (2021) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2021.104350 · Cited by 67 · see citing works
Looking different, feeling different: women’s reactions to risk-reducing breast and ovarian surgery
kConFab Psychosocial Group on behalf of the kConFab Investigators, Hallowell, N., Baylock, B., Heiniger, L., Butow, P. N., Patel, D., Meiser, B., Saunders, C., & Price, M. A. (2012) · Familial Cancer · doi:10.1007/s10689-011-9504-4 · Cited by 66 · see citing works
Vencken, P. M. L. H., Kriege, M., Hooning, M., Menke‐Pluymers, M. B., Heemskerk‐Gerritsen, B. A. M., van Doorn, L. C., Collée, M. M., Jager, A., van Montfort, C., Burger, C. W., et al. (2013) · Cancer · doi:10.1002/cncr.27839 · Cited by 40 · see citing works
van Driel, C., de Bock, G., Schroevers, M., & Mourits, M. (2019) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.15471 · Cited by 33 · see citing works
Nero, C., Ciccarone, F., Boldrini, L., Lenkowicz, J., Paris, I., Capoluongo, E. D., Testa, A. C., Fagotti, A., Valentini, V., & Scambia, G. (2020) · Scientific Reports · doi:10.1038/s41598-020-73505-2 · Cited by 31 · see citing works
van den Broek, A. J., de Ruiter, K., van 't Veer, L. J., Tollenaar, R. A. E. M., van Leeuwen, F. E., Verhoef, S., & Schmidt, M. K. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2014.161 · Cited by 18 · see citing works
Michel, A., Dorval, M., Chiquette, J., & Savard, J. (2024) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-024-00285-5 · Cited by 3 · see citing works
“A meta-analysis of women with a BRCA1/2 genetic mutation found that preventive sal-pingo-oophorectomy was associated with a strong reduction in ovarian cancer risk, ranging from 71 to 96%, and a 50% reduction in breast cancer risk [29].”
Background
- Authors
- Rebbeck, T. R., Kauff, N. D., & Domchek, S. M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Rebbeck, T. R.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01-13
- Volume
- 101
- Issue
- 2
- Pages
- 80-87
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- PMC
- PMC2639318
- OpenAlex
- W2132266605
- Cited by
- 939
- References
- 39
- Citations by year
- 2026: 39 · 2025: 40 · 2024: 51 · 2023: 42 · 2022: 57 · 2021: 51 · 2020: 60 · 2019: 51 · 2018: 56 · 2017: 81 · 2016: 60 · 2015: 49 · 2014: 57 · 2013: 59 · 2012: 63
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- National Cancer Institute (R01CA083855, R01CA102776)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Keywords
- risk-reducing salpingo-oophorectomy, BRCA1 mutation carriers, BRCA2 mutation carriers, breast cancer risk reduction, ovarian cancer risk reduction, fallopian tube cancer, hereditary cancer predisposition, cancer prevention, hazard ratio, timing of surgery, hysterectomy, oophorectomy, prophylactic hysterectomy
- MeSH terms
- Breast Neoplasms, Fallopian Tubes, Female, Heterozygote, Humans, Ovarian Neoplasms, Ovariectomy, Primary Prevention, Risk Factors, Cohort Studies, Odds Ratio, Case-Control Studies, Germ-Line Mutation, Risk Assessment, Genes, BRCA1, Genes, BRCA2, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
